Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients.

Senta FrolLana Podnar SernecLiam Korošec HudnikMišo ŠabovičJanja Pretnar Oblak

Published in: CNS drugs (2021)

Idarucizumab use in dabigatran-treated patients with AIS resulted in significantly more efficacious intravenous thrombolysis treatment and a non-significantly better outcome in dabigatran-treated patients with ICH compared with controls. There was no difference regarding complications.

Keyphrases

acute ischemic stroke
newly diagnosed
atrial fibrillation
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
pulmonary embolism
high dose
low dose
replacement therapy
optic nerve